- Report
- March 2024
- 195 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- March 2024
- 196 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- November 2023
- 144 Pages
Global
From €2400EUR$2,499USD£2,066GBP
- Report
- February 2024
- 112 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- January 2024
- 200 Pages
Global
From €3986EUR$4,150USD£3,432GBP
- Report
- August 2022
Global
From €4322EUR$4,500USD£3,721GBP
- Report
- July 2018
- 765 Pages
Global
From €21130EUR$22,000USD£18,192GBP
- Report
- December 2019
- 356 Pages
Global
From €10560EUR$10,995USD£9,092GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
- Report
- May 2020
- 151 Pages
Global
From €5158EUR$5,370USD£4,440GBP
Copaxone is a brand of medication used to treat multiple sclerosis (MS). It is a type of central nervous system (CNS) drug, which are used to treat a variety of neurological conditions. Copaxone is a synthetic form of a naturally occurring protein, and is administered as a subcutaneous injection. It is used to reduce the frequency of relapses in people with relapsing-remitting MS.
Copaxone is one of the most widely prescribed MS drugs, and is a major player in the CNS drug market. It is one of the few drugs approved for the treatment of MS, and is often used in combination with other medications.
The CNS drug market is highly competitive, with many companies offering similar products. Some of the major players in the Copaxone market include Teva Pharmaceuticals, Merck, and Biogen. Other companies in the market include Novartis, Sanofi, and Bayer. Show Less Read more
